Bath & Body Works, Inc. $BBWI Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lowered its position in Bath & Body Works, Inc. (NYSE:BBWI) by 2.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 53,018 shares of the company’s stock after selling 1,231 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Bath & Body Works were worth $1,588,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Parallel Advisors LLC increased its stake in shares of Bath & Body Works by 63.3% in the second quarter. Parallel Advisors LLC now owns 1,241 shares of the company’s stock worth $37,000 after acquiring an additional 481 shares during the period. Natixis Advisors LLC lifted its position in Bath & Body Works by 0.7% during the first quarter. Natixis Advisors LLC now owns 90,089 shares of the company’s stock valued at $2,732,000 after purchasing an additional 629 shares during the period. 1834 Investment Advisors Co. boosted its holdings in Bath & Body Works by 4.9% in the first quarter. 1834 Investment Advisors Co. now owns 16,736 shares of the company’s stock valued at $507,000 after purchasing an additional 779 shares during the last quarter. Geneos Wealth Management Inc. grew its position in Bath & Body Works by 217.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after purchasing an additional 801 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Bath & Body Works by 1.5% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 53,593 shares of the company’s stock valued at $1,625,000 after buying an additional 809 shares during the last quarter. Institutional investors and hedge funds own 95.14% of the company’s stock.

Bath & Body Works Stock Performance

Bath & Body Works stock opened at $23.88 on Friday. The stock has a market capitalization of $4.92 billion, a P/E ratio of 7.09, a P/E/G ratio of 0.86 and a beta of 1.52. The company’s fifty day moving average price is $27.15 and its 200 day moving average price is $29.00. Bath & Body Works, Inc. has a 1 year low of $23.79 and a 1 year high of $41.87.

Bath & Body Works (NYSE:BBWI) last posted its quarterly earnings data on Thursday, August 28th. The company reported $0.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.37. Bath & Body Works had a net margin of 9.88% and a negative return on equity of 48.43%. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.55 billion. During the same period last year, the firm posted $0.37 earnings per share. The company’s revenue was down .8% compared to the same quarter last year. Bath & Body Works has set its Q3 2025 guidance at 0.370-0.45 EPS. FY 2025 guidance at 3.350-3.600 EPS. Sell-side analysts predict that Bath & Body Works, Inc. will post 3.3 EPS for the current year.

Bath & Body Works Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 5th. Investors of record on Friday, August 22nd were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 3.4%. The ex-dividend date was Friday, August 22nd. Bath & Body Works’s payout ratio is presently 23.74%.

Wall Street Analyst Weigh In

BBWI has been the subject of several analyst reports. Telsey Advisory Group reissued an “outperform” rating and issued a $38.00 price objective on shares of Bath & Body Works in a report on Thursday, August 28th. Morgan Stanley decreased their price target on Bath & Body Works from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, September 12th. Citigroup lowered their price objective on Bath & Body Works from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, August 19th. UBS Group lowered their price objective on Bath & Body Works from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Friday, August 29th. Finally, Barclays cut their target price on shares of Bath & Body Works from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Monday, October 20th. Eleven analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Bath & Body Works has an average rating of “Moderate Buy” and a consensus price target of $36.39.

Bath & Body Works Profile

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.